Fintel reports that on April 21, 2025, B of A Securities upgraded their outlook for United Therapeutics (NasdaqGS:UTHR) from ...

As previously reported, BofA analyst Jason Gerberry upgraded United Therapeutics (UTHR) to Neutral from Underperform with an unchanged price ...

BofA upgraded United Therapeutics (UTHR) to Neutral from Underperform with a $314 price target Stay Ahead of the Market: Discover ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

It is worth considering United Therapeutics (UTHR), which belongs to the Zacks Medical - Drugs industry. This drugmaker has an established record of topping earnings estimates, especially when ...

Liquidia faced significant legal challenges from United Therapeutics, delaying the market entry of its PAH drug Yutrepia until after Tyvaso's patent expiry in 2025. Despite tentative FDA approval ...

Presented by Andrew Stine, United Therapeutics. Poster Session 1. Cardiology, Sunday, April 27, 6:00 – 7:00 p.m. ET: 447 – Clinical Correlations with Cardiac Power Output-to-Mass and Left ...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., April 02, 2025--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Great Place ...

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Great Place to Work® and Fortune magazine recognized the company as one of the Fortune 100 Best ...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Apr 2, 2025-- ...